SynthesisFrontiers in health services2025
Economic evaluation of intravenous iron formulations for patients with iron deficiency anemia: a systematic review.
Synthesis in Frontiers in health services, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Various intravenous iron formulations show great promise in the treatment of iron deficiency anemia (IDA), and economic evaluation results are becoming increasingly important as criteria for allocating healthcare resources. This study aimed to systematically evaluate the economics of six main intravenous iron formulations in the treatment of IDA. Methods: Computerized search of relevant studies in PubMed, Embase, Web of Science, and The Cochrane Library to collect economic evaluation of six intravenous iron formulations for the treatment of patients with IDA; the time limit for searching was from the establishment of the database to 30 July 2025. Two reviewers independently screened literature, extracted data, evaluated the quality of included studies using the Consolidated Health Economic Evaluations Reporting Standards 2022, and performed descriptive analyses. Results: Of the 2,288 articles retrieved, 17 studies were included, including five drugs, conducted in 10 different countries. Six studies compared ferric carboxymaltose (FCM) with iron sucrose (IS); two studies compared FCM, ferric derisomaltose (FDI), and IS; one study compared FCM, iron dextran (ID), and IS; one study compared FCM, IS, ID, and FDI at three dose levels; one study obtained an economic ranking for FCM, ID, IS, and ferrous gluconate (FG); five studies compared FDI and FCM; and one study compared FDI with IS. The overall quality of the included studies was high. A total of 13 studies conducted sensitivity analyses to check the robustness of their results. Conclusion: This review systematically evaluates the economic characteristics of the six main intravenous iron formulations for treating IDA. Current evidence suggests that the efficacy of FDI is better than IS, and the economic ranking of the four intravenous iron formulations can be summarized as FCM, ID, IS, and FG. Further research is needed to justify the economic comparison between FCM and FDI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.